Analyst Ratings For Baxter International Inc. (NYSE:BAX)
Today, Wells Fargo & Co reiterated its Outperform rating on Baxter International Inc. (NYSE:BAX) with a price target of $89.00.
There are 12 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Baxter International Inc. (NYSE:BAX) is Buy with a consensus target price of $77.60 per share, a potential 4.59% downside.
Some recent analyst ratings include
- 4/3/2019-Baxter International Inc. (NYSE:BAX) had its Outperform ➝ Outperform rating reiterated by Wells Fargo & Co with a $89.00 price target
- 2/1/2019-Baxter International Inc. (NYSE:BAX) gets upgraded to Equal Weight by Barclays with a price target of $72.00
- 2/1/2019-Baxter International Inc. (NYSE:BAX) had its Overweight rating reiterated by Piper Jaffray Companies with a $80.00 price target
- 1/2/2019-Baxter International Inc. (NYSE:BAX) gets upgraded to Buy by Citigroup with a price target of $76.00
- 12/17/2018-Baxter International Inc. (NYSE:BAX) has coverage initiated with a Outperform rating and $77.00 price target
- 11/27/2018-Baxter International Inc. (NYSE:BAX) has coverage initiated with a Buy rating and $80.00 price target
- On 3/29/2019 Scott Pleau, SVP, sold 9,710 with an average share price of $80.00 per share and the total transaction amounting to $776,800.00.
- On 3/18/2019 Giuseppe Accogli, SVP, sold 38,297 with an average share price of $76.78 per share and the total transaction amounting to $2,940,443.66.
- On 3/13/2019 John D Forsyth, Director, sold 1,500 with an average share price of $75.92 per share and the total transaction amounting to $113,880.00.
- On 3/1/2019 Thomas T Stallkamp, Director, sold 1,000 with an average share price of $75.16 per share and the total transaction amounting to $75,160.00.
- On 2/1/2019 Thomas T Stallkamp, Director, sold 1,638 with an average share price of $73.75 per share and the total transaction amounting to $120,802.50.
- On 1/31/2019 Jeanne K Mason, SVP, sold 37,274 with an average share price of $72.00 per share and the total transaction amounting to $2,683,728.00.
- On 1/18/2019 Thomas T Stallkamp, Director, sold 3,187 with an average share price of $70.00 per share and the total transaction amounting to $223,090.00.
About Baxter International Inc. (NYSE:BAX)
Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Recent Trading Activity for Baxter International Inc. (NYSE:BAX)
Shares of Baxter International Inc. closed the previous trading session at 81,24 −0,30 0,37 % with shares trading hands.
